About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 166 record(s)
Req # A-2021-001967
All documents submitted to Health Canada pursuant to the regulatory review that resulted in the Regulatory Decision Summary (ages 12-17) dated 2021-08-27 for the ModernaTX, Inc. (Moderna) SPIKEVAX COVID-19 vaccine. The full regulatory review decision from which the summary was generated. See https://covid-vaccine.canada.ca/covid-19-vaccine-moderna/product-details.Organization: Health Canada
February 2023
Req # A-2022-000424
All receipts for the expense referred to in Sessional Paper 8555-441-494, tabled in the House of Commons on June 8, 2022, with the following vendor, amount, date of expenditure, and file number: Essential Liquids Inc., $1,799.10, February 18th, 2022, 139209. timeframe of records to January 1, 2022 and July 4, 2022.Organization: Health Canada
February 2023
Req # A-2022-000484
All documents explaining why Health Canada changed its policy on or about May 12, 2020 which made it no longer necessary for cannabis growing license holders to obtain Health Canada’s approval to add a new operations area within an approved building already appearing on the license holder’s license.Organization: Health Canada
February 2023
Req # A-2022-000622
Updated Excel spreadsheet of loss-theft of opioid drug products reported to Health Canada from January 1, 1996 to August 10, 2022.Organization: Health Canada
February 2023
Req # A-2022-000852
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-09-16 for the medicinal ingredient Lamotrigine. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for lamotrigine which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-16.Organization: Health Canada
February 2023
Req # A-2022-000882
Information for all complaints posted against Searchlight Pharma Inc. - in relation to health product advertising incidents. All information in relation to incidents received by Health Canada and those referred to an Advertising Preclearance Agency (APA) from 2021-01-01 - 2022-09-27 in regards to product Addyi. All information in relation to complaints regarding the direct-to-consumer advertising of unauthorized claims.Organization: Health Canada
February 2023
Req # A-2022-000993
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-10-20 for the medicinal ingredient regorafenib. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for regorafenib which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-10-20.Organization: Health Canada
February 2023
Req # A-2022-001037
The written submissions by individuals and organizations during the regulatory public consultation period. The formal submissions made by all interest groups and individuals for the regulations below. Specific Regulations: SOR-2001-227: Marihuana Medical Access Regulations, Jun 14, 2001. SOR-2003- 387: Regulations Amending the Marihuana Medical Access Regulations, Dec 3, 2003. SOR/2005-177: Regulations Amending the Marihuana Medical Access Regulations, Jun 7, 2005. SOR-2013-119: Marihuana for Medical Purposes Regulations, Jun 6, 2013.Organization: Health Canada
February 2023
Req # A-2022-001097
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-11-10 for the medicinal ingredient sulfamethoxazole trimethoprim. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for sulfamethoxazole trimethoprim which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-11-10.Organization: Health Canada
February 2023
Req # A-2022-001116
Any documents or other communications to or from Health Canada, relating to the removal of Canadian Patent No. 2,712,614 from the Patent Register in respect of Drug Identification Numbers 02425483 and 02425491 on July 25, 2022.Organization: Health Canada
February 2023